Acrongenomics Inc.

Acrongenomics, Inc. is a U.S. publicly traded company (OTC Markets/AGNM) that focuses on developing and commercializing novel biotechnology platforms in the Life Science sector as well as introducing and developing promising new compounds in the Pharmaceutical sector. Our goal is to bring novel and realistic concepts to market by transforming scientific innovations into tangible, customer orientated applications.

As the global population escalates every year, medical providers are constantly seeking technologically advanced products and processes from diagnostics to treatment to monitoring patient diseases. We anticipate the technological changes we will inevitably encounter and strive to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

The company has its headquarters in London, England.

We were the first to identify the combination of microfluidics and light responsive polymers being developed by Molecular Vision in London as having the potential of completely revolutionizing the Point of Care (PoC) diagnostics market.
This lab on a chip diagnostic platform has the potential to produce simple to use compact, low cost, hand held device where the analytical capabilities of a number of standard pieces of laboratory equipment can be duplicated.
This means that a very wide range of diagnostic tests based on the same procedures that are used in the laboratory, will now be available to be undertaken in a physician’s office or even in the field (for example, trying to identify an outbreak of infectious disease in farm animals).

Acrongenomics has a stake in the Molecular Vision technology platform and its current patents. Furthermore and regardless of its shareholding in Molecular Vision, Acrongenomics is entitled to two separate forms of royalties in all fields of application of the lab on a chip platform.

Also Acrongenomics through its subsidiary Halldale Ventures Limited, holds the international patent of Compound X as an antilipidemic treatment, and financially supports its preclinical and further development. 
Compound X is a novel antilipidemic agent that lowers both the cholesterol and the triglyceride serum levels. Compound X’s action relays on a unique biochemical mechanism that is different from that of statins and the other known antilipidemic agents.